Hospira’s Inflectra is available in Canada

March 31, 2015 2:32 PM

Hospira announced the availability of Inflectra (infliximab) in Canada, the country’s first subsequent entry biologic (SEB) monoclonal antibody (mAb) therapy.

Approved by Health Canada, Inflectra is available to healthcare practitioners for the treatment of patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and plaque psoriasis.

An SEB (also referred to as a ‘biosimilar’ outside of Canada) is a biologic medicine made from a living organism or cell. SEBs deliver comparable clinical effects to their reference biologics while providing the opportunity for cost savings to the Canadian healthcare system.

“By providing subsequent entry biologic therapies, we can offer patients better access to high-quality, effective treatment options, and can help alleviate some of Canada’s healthcare costs,” said Gerry Stefanatos, corporate vice president, Canada and Australia/New Zealand, Hospira. “We are very proud to bring Inflectra to Canada — offering physicians, clinicians and patients a treatment option that maintains similar quality, efficacy and safety to its reference product.”

In addition, Hospira has developed an in-depth patient assistance program to help provide infusion-clinic access to qualifying patients across Canada, along with numerous other patient services.

Canada is truly a unique country in that the majority of infliximab infusions take place outside of hospitals. Hospira has focused on providing the best possible experience for patients prescribed Inflectra, from the moment they leave the physician’s office to the actual administration of the product in the infusion clinics,” continued Stefanatos.

Inflectra is biosimilar to the reference product Remicade® (infliximab), and was the first of its kind to be approved through the Health Canada SEB regulatory pathway. Remicade recorded sales of nearly CAD $800 million in Canada in 2014.

Hospira has the exclusive distribution rights to Inflectra in several major markets, including Canada. Bringing SEBs to Canada is the next major step towards driving healthcare cost savings and improving patient access to high-quality, more affordable biologic drugs. Biologic products, including SEBs, treat some of the most widespread and difficult-to-treat illnesses, such as cancer and chronic kidney diseases, as well as autoimmune diseases.

Patients and healthcare professionals outside North America have long had access to biosimilars — the European Medicines Agency (EMA) approved the first biosimilar in 2006. Inflectra is currently available in 26 countries across Europe, and during the last seven years, Hospira has provided more than 10 million doses of  biosimilars to patients in Europe and Australia.

Source: Hospira press release

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!